The Clinical Effect of Zoledronic Acid Combined with Teriparatide in Perverting Recurrent Fracture of Osteoporotic Vertebral Compressive Fractures in the Elderly after Percutaneous Kyphoplasty — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
The Clinical Effect of Zoledronic Acid Combined with Teriparatide in Perverting Recurrent Fracture of Osteoporotic Vertebral Compressive Fractures in the Elderly after Percutaneous Kyphoplasty
Department of Surgery, Graduate School of Hebei North University, Zhangjiakou, China
,
Department of Orthopaedics, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China
,
Department of Orthopaedics, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China
1 Department of Surgery, Graduate School of Hebei North University, Zhangjiakou, China
2 Department of Orthopaedics, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China
3 Department of Orthopaedics, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China
Background: Zoledronic acid and teriparatide have been proved to be effective in improving bone metabolism and preventing fractures, but there is no clear clinical report on the efficacy of their combined application. Purpose: To discuss the clinical effect of zoledronic acid combined with teriparatide in perverting recurrent fracture of osteoporotic vertebral compressive fractures (OVCF) in the elderly after percutaneous kyphoplasty (PKP). Method: A randomized clinical trial was conducted at the First Affiliated Hospital of Hebei North University in China from September 2018 and September 2019. A total of 60 patients with OVCF were enrolled in the study (zoledronic acid: 20 cases; teriparatide: 20 cases; zoledronic acid + teriparatide: 20 cases). Observe and compare the changes of bone mineral density (BMD), pro-collagen type I N-terminal propeptide (PINP) and cross-linked C-terminal telopeptide of type I collagen ( β -CTX) before surgery, 6 months and 1 year after surgery. At the same time, secondary fracture events and adverse reaction events were recorded during the follow-up period. Results: After normalized treatment, the bone metabolism indexes of PINP and β -CTX were improved and BMD was increased in three groups. Adverse Reactions: There was no statistical significance in the incidence of fever, gastrointestinal reactions and myalgia among the three groups (P > 0.05). The incidence of recurrent fractures in group A was higher than that in group C (P < 0.05), but there was no significant difference between group B and group C (P > 0.05). Conclusion: Zoledronic acid combined with teriparatide is superior to Zoledronic acid in preventing the risk of recurrent fracture after PKP for old patients with OVCF, but it has no significant advantage over teriparatide.
Cavalier, E., Lukas, P., Bottani, M., et al. (2020) European Biological Variation Study (EuBIVAS): Within- and Between-Subject Biological Variation Estimates of β-Isomerized C-Terminal Telopeptide of Type I Collagen (β-CTX), N-Terminal Propeptide of Type I Collagen (PINP), Osteocalcin, Intact Fibroblast Growth Factor 23 and Uncarboxylated-Unphosphorylated Matrix-Gla Protein-A Cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism. Osteoporosis International, 31, 1461-1470. https://doi.org/10.1007/s00198-020-05362-8
Cheng, C., Wentworth, K. and Shoback, D.M. (2020) New Frontiers in Osteoporosis Therapy. Annual Review of Medicine, 71, 277-288. https://doi.org/10.1146/annurev-med-052218-020620
Wang, F., Wang, L.F., Miao, D.C., et al. (2018) Which One Is More Effective for the Treatment of Very Severe Osteoporotic Vertebral Compression Fractures: PVP or PKP? Journal of Pain Research, 11, 2625-2631. https://doi.org/10.2147/JPR.S179022
Yang, H., Liu, H., Wang, S., et al. (2016) Review of Percutaneous Kyphoplasty in China. Spine (Phila Pa 1976), 41, B52-B58. https://doi.org/10.1097/BRS.0000000000001804
Zuo, X.H., Zhu, X.P., Bao, H.G., et al. (2018) Network Meta-Analysis of Percutaneous Vertebroplasty, Percutaneous Kyphoplasty, Nerve Block, and Conservative Treatment for Nonsurgery Options of Acute/Subacute and Chronic Osteoporotic Vertebral Compression Fractures (OVCFs) in Short-Term and Long-Term Effects. Medicine (Baltimore), 97, e11544. https://doi.org/10.1097/MD.0000000000011544
Li, H.M., Zhang, R.J., Gao, H., et al. (2018) New Vertebral Fractures after Osteoporotic Vertebral Compression Fracture between Balloon Kyphoplasty and Nonsurgical Treatment PRISMA. Medicine (Baltimore), 97, e12666. https://doi.org/10.1097/MD.0000000000012666
Ren, H.-L., Jiang, J.-M., Chen, J.-T., et al. (2015) Risk Factors of New Symptomatic Vertebral Compression Fractures in Osteoporotic Patients Undergone Percutaneous Vertebroplasty. European Spine Journal, 24, 750-758.
Reid, I.R., Horne, A.M., Mihov, B., et al. (2019) Anti-Fracture Efficacy of Zoledronate in Subgroups of Osteopenic Postmenopausal Women: Secondary Analysis of a Randomized Controlled Trial. Journal of Internal Medicine, 286, 221-229. https://doi.org/10.1111/joim.12901
Yishake, M., Yasen, M., Jiang, L., et al. (2018) Effects of Combined Teriparatide and Zoledronic Acid on Posterior Lumbar Vertebral Fusion in an Aged Ovariectomized Rat Model of Osteopenia. Journal of Orthopaedic Research, 36, 937-944. https://doi.org/10.1002/jor.23682
Dhillon, S. (2016) Zoledronic Acid (Reclast ® , Aclasta ® ): A Review in Osteoporosis. Drugs, 76, 1683-1697. https://doi.org/10.1007/s40265-016-0662-4
Cosman, F., Eriksen, E.F., Recknor, C., et al. (2011) Effects of Intravenous Zoledronic Acid plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 26, 503-511. https://doi.org/10.1002/jbmr.238
Zhang, J., Yan, B., Chen, Z., et al. (2020) Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty. Asian Spine Journal. https://doi.org/10.31616/asj.2020.0282
Mazziotti, G., Bilezikian, J., Canalis, E., et al. (2012) New Understanding and Treatments for Osteoporosis. Endocrine, 41, 58-69. https://doi.org/10.1007/s12020-011-9570-2
Hiligsmann, M., Evers, S.M., Ben Sedrine, W., et al. (2015) A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis. Pharmacoeconomics, 33, 205-224. https://doi.org/10.1007/s40273-014-0231-1
Szulc, P. (2018) Bone Turnover: Biology and Assessment Tools. Best Practice & Research Clinical Endocrinology & Metabolism, 32, 725-738. https://doi.org/10.1016/j.beem.2018.05.003
Berry, S.D., Dufour, A.B., Travison, T.G., et al. (2018) Changes in Bone Mineral Density (BMD): A Longitudinal Study of Osteoporosis Patients in the Real-World Setting. Archives of Osteoporosis, 13, 124. https://doi.org/10.1007/s11657-018-0528-3
Kapuš, O., Gába, A. and Lehnert, M. (2020) Relationships between Bone Mineral Density, Body Composition, and Isokinetic Strength in Postmenopausal Women. Bone Reports, 12, Article ID: 100255. https://doi.org/10.1016/j.bonr.2020.100255
Johansson, H., Kanis, J.A., Oden, A., et al. (2009) BMD, Clinical Risk Factors and Their Combination for Hip Fracture Prevention. Osteoporosis International, 20, 1675-1682. https://doi.org/10.1007/s00198-009-0845-x
Højsager, F.D., Rand, M.S., Pedersen, S.B., et al. (2019) Fracture-Induced Changes in Biomarkers CTX, PINP, OC, and BAP—A Systematic Review. Osteoporosis International, 30, 2381-2389. https://doi.org/10.1007/s00198-019-05132-1
Szulc, P., Naylor, K., Hoyle, N.R., et al. (2017) Use of CTX-I and PINP as Bone Turnover Markers: National Bone Health Alliance Recommendations to Standardize Sample Handling and Patient Preparation to Reduce Pre-Analytical Variability. Osteoporosis International, 28, 2541-2556. https://doi.org/10.1007/s00198-017-4082-4
Yang, S.W., Ma, R.J., Zhao, J.J., et al. (2018) Clinical Significance of the Ratio of Serum Beta-CTX/PINP in Multiple Myeloma Bone Diseases and Bone Metastases. Chinese Medical Journal, 98, 2583-2587.
Krege, J.H., Lane, N.E., Harris, J.M., et al. (2014) PINP as a Biological Response Marker during Teriparatide Treatment for Osteoporosis. Osteoporosis International, 25, 2159-2171. https://doi.org/10.1007/s00198-014-2646-0
Niimi, R., Kono, T., Nishihara, A., et al. (2014) An Algorithm Using the Early Changes in PINP to Predict the Future BMD Response for Patients Treated with Daily Teriparatide. Osteoporosis International, 25, 377-384. https://doi.org/10.1007/s00198-013-2426-2
Bhattoa, H.P., Cavalier, E., Eastell, R., et al. (2021) Analytical Considerations and Plans to Standardize or Harmonize Assays for the Reference Bone Turnover Markers PINP and β-CTX in Blood. Clinica Chimica Acta, 515, 16-20. https://doi.org/10.1016/j.cca.2020.12.023
Center, J.R. (2017) Fracture Burden: What Two and a Half Decades of Dubbo Osteoporosis Epidemiology Study Data Reveal about Clinical Outcomes of Osteoporosis. Current Osteoporosis Reports, 15, 88-95. https://doi.org/10.1007/s11914-017-0352-5
Yao, X., Xu, Z. and Du, X. (2019) PKP/PVP Combine Chemotherapy in the Treatment of Multiple Myeloma Patients with Vertebral Pathological Fractures: Minimum 3-Year Follow-Up of 108 Cases. Journal of Orthopaedic Surgery and Research, 14, 42. https://doi.org/10.1186/s13018-019-1078-0
Zhou, T., Lin, H., Wang, H., et al. (2017) Comparative Study on the Biomechanics between Improved PVP and Traditional PKP in the Treatment of Vertebral Peripheral Wall Damage-Type OVCF. Experimental and Therapeutic Medicine, 14, 575-580. https://doi.org/10.3892/etm.2017.4542
Lavelle, W.F. and Cheney, R. (2006) Recurrent Fracture after Vertebral Kyphoplasty. The Spine Journal, 6, 488-493. https://doi.org/10.1016/j.spinee.2005.10.013
Bahşi, R., Atmiş, V., Turgut, T., et al. (2020) May Zoledronic Acid Have Negative Effects on Cognition and Muscle Performance? Irish Journal of Medical Science, 189, 191-196. https://doi.org/10.1007/s11845-019-02086-5
Ouyang, Z., Li, H., Zhai, Z., et al. (2018) Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma. Current Drug Targets, 19, 409-421. https://doi.org/10.2174/1573399811666150615145409
Coleman, R., Burkinshaw, R., Winter, M., et al. (2011) Zoledronic Acid. Expert Opinion on Drug Safety, 10, 133-145. https://doi.org/10.1517/14740338.2011.540387
Greenspan, S.L., Vujevich, K., Britton, C., et al. (2018) Teriparatide for Treatment of Patients with Bisphosphonate-Associated Atypical Fracture of the Femur. Osteoporosis International, 29, 501-506. https://doi.org/10.1007/s00198-017-4286-7
Lindsay, R., Krege, J.H., Marin, F., et al. (2016) Teriparatide for Osteoporosis: Importance of the Full Course. Osteoporosis International, 27, 2395-2410. https://doi.org/10.1007/s00198-016-3534-6
Saag, K.G., Shane, E., Boonen, S., et al. (2007) Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. The New England Journal of Medicine, 357, 2028-2039. https://doi.org/10.1056/NEJMoa071408
Murphy, P.Z., Iranikhah, M., Deas, C.M., et al. (2018) Fracture Risk Following Discontinuation of Teriparatide: A Review of the Literature. Consultant Pharmacist, 33, 365-375. https://doi.org/10.4140/TCP.n.2018.365
Cosman, F. (2014) Anabolic and Antiresorptive Therapy for Osteoporosis: Combination and Sequential Approaches. Current Osteoporosis Reports, 12, 385-395. https://doi.org/10.1007/s11914-014-0237-9
Leder, B.Z. (2018) Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy. JBMR Plus, 2, 62-68. https://doi.org/10.1002/jbm4.10041
Suzuki, H. and Takeuchi, Y. (2012) Combination or Sequential Treatment Using PTH and Anti-Resorption Therapies. Clinical Calcium, 22, 415-420.
Diab, D.L. and Watts, N.B. (2013) Postmenopausal Osteoporosis. Current Opinion in Endocrinology, Diabetes and Obesity, 20, 501-509. https://doi.org/10.1097/01.med.0000436194.10599.94
Vasikaran, S.D., Bhattoa, H.P., Eastell, R., et al. (2020) Harmonization of Commercial Assays for PINP; the Way Forward. Osteoporosis International, 31, 409-412. https://doi.org/10.1007/s00198-020-05310-6